Climb Bio Inc
NASDAQ:CLYM

Watchlist Manager
Climb Bio Inc Logo
Climb Bio Inc
NASDAQ:CLYM
Watchlist
Price: 3.75 USD -6.25% Market Closed
Market Cap: 255.7m USD

Climb Bio Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Climb Bio Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Climb Bio Inc
NASDAQ:CLYM
Cash from Operating Activities
-$15.6m
CAGR 3-Years
24%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Climb Bio Inc
Glance View

Market Cap
255.7m USD
Industry
Biotechnology

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.

CLYM Intrinsic Value
Not Available

See Also

What is Climb Bio Inc's Cash from Operating Activities?
Cash from Operating Activities
-15.6m USD

Based on the financial report for Dec 31, 2024, Climb Bio Inc's Cash from Operating Activities amounts to -15.6m USD.

What is Climb Bio Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-25%

Over the last year, the Cash from Operating Activities growth was 24%. The average annual Cash from Operating Activities growth rates for Climb Bio Inc have been 24% over the past three years , -25% over the past five years .

Back to Top